ORKA vs ARQT vs REGN vs DAWN vs PFE

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Oruka Therapeutics, Inc. (ORKA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus Pfizer Inc. at 19. 5x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Oruka Therapeutics, Inc.

(ORKA) delivered a total return of +115. 2%, compared to -39. 5% for Arcutis Biotherapeutics, Inc. (ARQT). Over 10 years, the gap is even starker: REGN returned +90. 0% versus ORKA's -89. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.

(DAWN) is the lower-risk stock at 0. 35β versus Oruka Therapeutics, Inc. 's 1. 61β — meaning ORKA is approximately 355% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Oruka Therapeutics, Inc. (ORKA) carries a lower debt/equity ratio of 0% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -67. 8% for Day One Biopharmaceuticals, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -80. 8% for DAWN. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 9x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 68. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORKA: 112. 9% to $136. 38.

In this comparison, PFE (6.

5% yield), REGN (0. 5% yield) pay a dividend. ORKA, ARQT, DAWN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Oruka Therapeutics, Inc. (ORKA) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +29. 6%, ORKA: -89. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ORKA is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; DAWN is a small-cap high-growth stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while ORKA, ARQT, REGN, DAWN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.